{"id":58634,"date":"2026-03-03T12:59:07","date_gmt":"2026-03-03T04:59:07","guid":{"rendered":"https:\/\/flcube.com\/?p=58634"},"modified":"2026-03-03T12:59:07","modified_gmt":"2026-03-03T04:59:07","slug":"boehringer-ingelheim-licenses-sitryx-autoimmune-program-500m-deal-for-oral-disease-modifying-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58634","title":{"rendered":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy"},"content":{"rendered":"\n<p><strong>Boehringer Ingelheim (BI)<\/strong> announced a <strong>licensing agreement<\/strong> with <strong>Sitryx Therapeutics<\/strong>, obtaining <strong>exclusive global rights<\/strong> to the UK biotech&#8217;s <strong>pre\u2011clinical small molecule program<\/strong>. The asset is expected to become a <strong>novel oral, potentially disease\u2011modifying therapy<\/strong> for <strong>autoimmune and inflammatory diseases<\/strong>, expanding Boehringer&#8217;s immunology pipeline beyond its established respiratory and cardiometabolic franchises.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Sitryx Therapeutics (UK)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Boehringer Ingelheim (Germany)<\/td><\/tr><tr><td><strong>Licensed Asset<\/strong><\/td><td>Pre\u2011clinical small molecule program<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive global rights<\/td><\/tr><tr><td><strong>Therapeutic Potential<\/strong><\/td><td>Novel oral disease\u2011modifying therapy for autoimmune\/inflammatory diseases<\/td><\/tr><tr><td><strong>Boehringer Responsibilities<\/strong><\/td><td>Full R&amp;D, clinical development, commercialization<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront + near\u2011term payments + milestones <strong>&gt;\u202fUSD\u202f500\u202fmillion<\/strong> + tiered royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease\u2011Modifying Potential<\/strong><\/td><td>Addresses unmet need for therapies altering disease course vs. symptom management<\/td><\/tr><tr><td><strong>Oral Administration<\/strong><\/td><td>Improved patient compliance vs. injectable biologics (adalimumab, etanercept)<\/td><\/tr><tr><td><strong>Small Molecule Advantage<\/strong><\/td><td>Manufacturing scalability, cost efficiency, and distribution simplicity vs. biologics<\/td><\/tr><tr><td><strong>Autoimmune Expansion<\/strong><\/td><td>Diversifies Boehringer beyond respiratory (Spiriva) and diabetes (Jardiance) into immunology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sitryx-positioning\">Sitryx Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company Profile<\/strong><\/td><td>UK\u2011based biotech specializing in immunometabolism and novel autoimmune mechanisms<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary small molecule discovery platform targeting immune cell metabolism<\/td><\/tr><tr><td><strong>Deal Validation<\/strong><\/td><td>$500M+ potential validates pre\u2011clinical platform and attracts follow\u2011on investment<\/td><\/tr><tr><td><strong>Future Upside<\/strong><\/td><td>Tiered royalties provide long\u2011term revenue stream post\u2011approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Autoimmune Market Size<\/strong><\/td><td>&gt;\u202f$150\u202fbillion globally; dominated by anti\u2011TNF biologics with growing demand for oral alternatives<\/td><\/tr><tr><td><strong>Disease\u2011Modifying Gap<\/strong><\/td><td>Most current therapies manage symptoms; true disease modification remains rare (e.g., methotrexate in RA)<\/td><\/tr><tr><td><strong>Oral JAK\/SYK Competition<\/strong><\/td><td>Pfizer&#8217;s Xeljanz, BMS&#8217;s deucravacitinib established oral market; novel mechanisms required for differentiation<\/td><\/tr><tr><td><strong>Boehringer Immunology Build<\/strong><\/td><td>Follows recent acquisitions (e.g., AMAL Therapeutics) signaling strategic focus on immunology innovation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding pre\u2011clinical to clinical transition, disease\u2011modifying mechanism validation, and autoimmune indication selection. Actual results may differ due to risks including target engagement failure, competitive oral immunology program advancements, and autoimmune clinical trial complexity.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58635,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,390,4634],"class_list":["post-58634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-boehringer-ingelheim","tag-sitryx-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to the UK biotech&#039;s pre\u2011clinical small molecule program. The asset is expected to become a novel oral, potentially disease\u2011modifying therapy for autoimmune and inflammatory diseases, expanding Boehringer&#039;s immunology pipeline beyond its established respiratory and cardiometabolic franchises.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58634\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to the UK biotech&#039;s pre\u2011clinical small molecule program. The asset is expected to become a novel oral, potentially disease\u2011modifying therapy for autoimmune and inflammatory diseases, expanding Boehringer&#039;s immunology pipeline beyond its established respiratory and cardiometabolic franchises.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58634\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T04:59:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy\",\"datePublished\":\"2026-03-03T04:59:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0302.webp\",\"keywords\":[\"Auto-immune\",\"Boehringer Ingelheim\",\"Sitryx Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58634#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58634\",\"name\":\"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0302.webp\",\"datePublished\":\"2026-03-03T04:59:07+00:00\",\"description\":\"Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to the UK biotech's pre\u2011clinical small molecule program. The asset is expected to become a novel oral, potentially disease\u2011modifying therapy for autoimmune and inflammatory diseases, expanding Boehringer's immunology pipeline beyond its established respiratory and cardiometabolic franchises.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58634\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58634#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to the UK biotech's pre\u2011clinical small molecule program. The asset is expected to become a novel oral, potentially disease\u2011modifying therapy for autoimmune and inflammatory diseases, expanding Boehringer's immunology pipeline beyond its established respiratory and cardiometabolic franchises.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58634","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy","og_description":"Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to the UK biotech's pre\u2011clinical small molecule program. The asset is expected to become a novel oral, potentially disease\u2011modifying therapy for autoimmune and inflammatory diseases, expanding Boehringer's immunology pipeline beyond its established respiratory and cardiometabolic franchises.","og_url":"https:\/\/flcube.com\/?p=58634","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T04:59:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58634#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58634"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy","datePublished":"2026-03-03T04:59:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58634"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58634#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp","keywords":["Auto-immune","Boehringer Ingelheim","Sitryx Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58634#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58634","url":"https:\/\/flcube.com\/?p=58634","name":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58634#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58634#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp","datePublished":"2026-03-03T04:59:07+00:00","description":"Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to the UK biotech's pre\u2011clinical small molecule program. The asset is expected to become a novel oral, potentially disease\u2011modifying therapy for autoimmune and inflammatory diseases, expanding Boehringer's immunology pipeline beyond its established respiratory and cardiometabolic franchises.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58634#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58634"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58634#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58634#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Licenses Sitryx Autoimmune Program \u2013 $500M+ Deal for Oral Disease\u2011Modifying Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58634"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58634\/revisions"}],"predecessor-version":[{"id":58636,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58634\/revisions\/58636"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58635"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}